Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran
Cherub, Jane
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Tinjauan atas Angiotensin Receptor Blocker Generasi Baru Cherub, Jane
Cermin Dunia Kedokteran Vol 47, No 10 (2020): Optalmologi
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (191.425 KB) | DOI: 10.55175/cdk.v47i10.1088

Abstract

Angiotensin receptor blockers (ARB) yang bekerja menghambat reseptor AngII-AT1 secara selektif direkomendasikan sebagai agen antihipertensi lini pertama. Saat ini terdapat 8 varian ARB di pasaran. Selain efek antagonisasinya terhadap AT1, ARB generasi baru memiliki mekanisme tambahan yang dapat menarget hipertensi, penyakit kardiovaskular, dan diabetes. ARB generasi baru juga memblokir reseptor endotelin, berfungsi sebagai donor oksida nitrat, menghambat aktivitas neprilysin dan meningkatkan kadar peptida natriuretik, atau merangsang peroxisome proliferatoractivated receptor gamma (PPARγ). ARB generasi baru dapat memiliki nilai klinis dan manfaat terapeutik lebih besar daripada hanya melalui penghambatan reseptor AT1.Angiotensin receptor blockers (ARBs) works by selectively blocking AngII-AT1 receptors; it is recommended as a first-line antihypertensive agent. Currently there are 8 variants of ARB in the market. In addition to its AT1 antagonist effect, new generation of ARB can have additional mechanisms on hypertension, cardiovascular disease and diabetes. New generation ARBs also block endothelial receptors, as nitric oxide donors, inhibit neprilysin activity and increase levels of natriuretic peptides, or stimulate peroxisome proliferator-activated gamma receptors (PPARγ). New generation of ARBs can have considerable clinical value and provide greater therapeutic benefits.
Terapi Antikoagulan pada COVID-19 Cherub, Jane
Cermin Dunia Kedokteran Vol 48, No 6 (2021): Kardiologi
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (160.547 KB) | DOI: 10.55175/cdk.v48i6.1436

Abstract

Coronavirus disease-2019 (COVID-19) yang disebabkan infeksi Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) terutama bermanifestasi sebagai infeksi pernapasan, dengan salah satu komplikasi gangguan pembekuan darah yang dapat menyebabkan kesakitan hingga kematian. Dijumpai aktivasi kaskade koagulasi tidak terkontrol akibat berbagai efek sitokin proinflamasi yang dapat menyebabkan koagulopati konsumtif termasuk sepsis induced coagulopathy (SIC) dan disseminated intravascular coagulation (DIC). Fondaparinux dapat menjadi alternatif untuk pasien COVID-19 rawat inap. Tromboprofilaksis extended dengan LMWH atau direct oral anticoagulants (DOAC) harus dipertimbangkan pada pasien COVID-19 dengan risiko perdarahan rendahCoronavirus disease-2019 (COVID-19) caused by Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) mainly manifests as a respiratory infection, with complications of blood clotting disorders in severe infection which can cause severe illness to death. Uncontrolled activation of the coagulation cascade due to various effects of proinflammatory cytokines can result inconsumptive coagulopathy. Coagulation disorders can occur including sepsis-induced coagulopathy (SIC) and disseminated intravascular coagulation (DIC). Unfractionated heparin (UFH) and lowmolecular-weight heparin (LMWH) are widely used in the management of COVID-19 patients. Fondaparinux may be an alternative. Extended thromboprophylaxis with LMWH or direct oral anticoagulants (DOAC) with a low risk of bleeding should be considered in COVID-19patients. 
Co-Authors